瑞士的临床试验预算方法 - - 一项元研究研究
Alexandra Griessbach1, Malena Chiaborelli2,3, Klaus Ehrlich4
1CLEAR-Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland. alexandranatacha.griessbach@usb.ch.
Trials
|May 14, 2025
概括
瑞士的临床试验预算缺乏标准化和用户测试,导致资金问题. 建议改善这些实践,可能使用比利时KCE工具作为模型,以提高研究效率.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 临床试验管理 临床试验管理
- 医疗保健经济学 医疗经济学
背景情况:
- 临床试验是资源密集型的,在瑞士,临床试验面临预算高估和资金过高的挑战.
- 这些问题可能会导致试验中止和浪费研究资源.
- 本研究解决了在瑞士调查当前临床试验预算实践的需要.
研究的目的:
- 调查和分析目前用于估计瑞士临床试验预算的方法和工具.
- 确定现有预算方法的差距和需要改进的领域.
主要方法:
- 检查了7个瑞士临床试验单位 (CTU) 和瑞士国家科学基金会 (SNSF) 的预算工具和方法.
- 将瑞士的方法与比利时医疗保健知识中心 (KCE) 的公开预算工具进行了比较.
- 收集关于用户测试,成本项的可用性和每个方法的成本范围的数据.
主要成果:
- 在瑞士中央工会使用的预算计算方法中发现了显著的异质性.
- 瑞士审查的任何工具或方法都没有经过用户测试,也没有提供可靠的成本范围.
- 相比之下,比利时的KCE工具经过了用户测试,并提供了详细的成本项目和指导.
结论:
- 改善瑞士的临床试验预算需要标准化成本项目和实施用户测试的方法.
- 比利时的KCE工具可以作为一个有价值的参考来加强瑞士的预算实践.
- 标准化和用户反对于有效的临床试验资金和执行至关重要.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Hazard Ratio
72
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
72
Actuarial Approach
49
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
49
Kaplan-Meier Approach
62
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
62
Comparing the Survival Analysis of Two or More Groups
99
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
99
Cancer Survival Analysis
311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311


